Mirexus Biotechnologies Inc. Creates Glysantis Inc. to Explore Biomedical Uses of new nanomaterial
June 21, 2016 - Guelph, ON.
Mirexus Biotechnologies Inc. (MBI), a guelph-based nanomaterials company, has created a wholly-owned subsidiary called Glysantis Inc., to explore biomedical applications of a novel nanomaterial - NanoDendrix phytoglycogen - safe, monodisperse and biodegradable nanoparticles extracted from sweet corn.
New frontiers in Nanomedicine
Glysantis Inc. will engage in exploratory research & development, in collaboration with researchers at Ontario universities, to understand how NanoDendrix particles interact with biological systems and therapeutic compounds.
"We are excited to launch Glysantis with the mission to identify and develop promising biopharmaceutical applications of our unique nanoparticles." - Phil Whiting, President & CEO, MBI
About Mirexus Biotechnologies Inc. (MBI)
Mirexus Biotechnologies Inc. is a biomaterials company based in Guelph, Ontario. MBI has developed a novel, proprietary nanotechnology platform based on polysaccharide nanoparticles that can be used in a wide variety of markets ranging from cosmetics to nutraceuticals to biomedical applications in animal and human health. Originally developed in the University of Guelph in the laboratories of Professor John Dutcher; this technology is now being marketed globally.
Dr. Phil Whiting, CEO Glysantis Inc. 1-905-339-9907 email@example.com